AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
By Morana Vojnic, MD, MBA
Leptomeningeal disease (LMD) is becoming more common simply because patients with actionable mutations are living longer
Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
By Morana Vojnic, MD, MBA
Leptomeningeal disease (LMD) is becoming more common simply because patients with actionable mutations are living longer
Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
By Morana Vojnic, MD, MBA
Leptomeningeal disease (LMD) is becoming more common simply because patients with actionable mutations are living longer
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors
By Jerome Graber, MD, MPH
Glioblastoma outcomes with temozolomide depend heavily on MGMT methylation status, a distinction worth revisiting given how often it gets lost in practice.
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors
By Jerome Graber, MD, MPH
Glioblastoma outcomes with temozolomide depend heavily on MGMT methylation status, a distinction worth revisiting given how often it gets lost in practice.
Rethinking Glioblastoma Care: Methylation Status, Tumor Treating Fields, and IDH Inhibitors
By Jerome Graber, MD, MPH
Glioblastoma outcomes with temozolomide depend heavily on MGMT methylation status, a distinction worth revisiting given how often it gets lost in practice.
Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
By Carolina Schinke, MD
CAR-T cell therapy and bispecific antibodies have transformed relapsed multiple myeloma, but sequencing matters.
Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
By Carolina Schinke, MD
CAR-T cell therapy and bispecific antibodies have transformed relapsed multiple myeloma, but sequencing matters.
Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
By Carolina Schinke, MD
CAR-T cell therapy and bispecific antibodies have transformed relapsed multiple myeloma, but sequencing matters.
The Silent Ecosystem Within Clinical Trials
By Zoë Swainson, MHA
Clinical trial outcomes do not emerge solely by science. They also emerge from an invisible ecosystem of trust, coordination, compassion and operational excellence.
The Silent Ecosystem Within Clinical Trials
By Zoë Swainson, MHA
Clinical trial outcomes do not emerge solely by science. They also emerge from an invisible ecosystem of trust, coordination, compassion and operational excellence.
The Silent Ecosystem Within Clinical Trials
By Zoë Swainson, MHA
Clinical trial outcomes do not emerge solely by science. They also emerge from an invisible ecosystem of trust, coordination, compassion and operational excellence.
HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer
By Manik Amin, MD
Treatment selection for metastatic gastroesophageal adenocarcinoma now proceeds through a structured biomarker sequence.
HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer
By Manik Amin, MD
Treatment selection for metastatic gastroesophageal adenocarcinoma now proceeds through a structured biomarker sequence.
HER2-Directed Therapy Is Redefining Frontline Treatment for Gastroesophageal Cancer
By Manik Amin, MD
Treatment selection for metastatic gastroesophageal adenocarcinoma now proceeds through a structured biomarker sequence.
Novel Agents and MRD-Guided Therapy Are Reshaping Frontline Lymphoma Care
By Joe Schroers-Martin, MD
Bruton's tyrosine kinase (BTK) inhibitor combinations now anchor frontline mantle cell lymphoma treatment across age and fitness categories, including chemotherapy-free regimens for older patients and TP53-mutated disease.
Novel Agents and MRD-Guided Therapy Are Reshaping Frontline Lymphoma Care
By Joe Schroers-Martin, MD
Bruton's tyrosine kinase (BTK) inhibitor combinations now anchor frontline mantle cell lymphoma treatment across age and fitness categories, including chemotherapy-free regimens for older patients and TP53-mutated disease.
Novel Agents and MRD-Guided Therapy Are Reshaping Frontline Lymphoma Care
By Joe Schroers-Martin, MD
Bruton's tyrosine kinase (BTK) inhibitor combinations now anchor frontline mantle cell lymphoma treatment across age and fitness categories, including chemotherapy-free regimens for older patients and TP53-mutated disease.
Advanced Chondrosarcoma Finally Has Systemic Treatment Options Under Study
By Varun Monga, MBBS
Conventional chondrosarcoma has historically had no approved systemic therapy given its resistance to chemotherapy and radiation.
Advanced Chondrosarcoma Finally Has Systemic Treatment Options Under Study
By Varun Monga, MBBS
Conventional chondrosarcoma has historically had no approved systemic therapy given its resistance to chemotherapy and radiation.
Advanced Chondrosarcoma Finally Has Systemic Treatment Options Under Study
By Varun Monga, MBBS
Conventional chondrosarcoma has historically had no approved systemic therapy given its resistance to chemotherapy and radiation.
Autologous Transplant in Multiple Myeloma: Still the Standard as Quadruplet Therapy and Cellular Immunotherapy Advance
By Jason Chandler, MD
Autologous stem cell transplant has anchored newly diagnosed multiple myeloma treatment for decades, and every major guideline body still recommends it for eligible patients.
Autologous Transplant in Multiple Myeloma: Still the Standard as Quadruplet Therapy and Cellular Immunotherapy Advance
By Jason Chandler, MD
Autologous stem cell transplant has anchored newly diagnosed multiple myeloma treatment for decades, and every major guideline body still recommends it for eligible patients.
Autologous Transplant in Multiple Myeloma: Still the Standard as Quadruplet Therapy and Cellular Immunotherapy Advance
By Jason Chandler, MD
Autologous stem cell transplant has anchored newly diagnosed multiple myeloma treatment for decades, and every major guideline body still recommends it for eligible patients.
Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation
By Putao Cen, MD
Perioperative intensification is reshaping treatment for high-risk localized and metastatic castration-sensitive prostate cancer.
Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation
By Putao Cen, MD
Perioperative intensification is reshaping treatment for high-risk localized and metastatic castration-sensitive prostate cancer.
Perioperative Intensification in High-Risk Prostate Cancer: PROTEUS, TALAPRO-3, and Treatment De-Escalation
By Putao Cen, MD
Perioperative intensification is reshaping treatment for high-risk localized and metastatic castration-sensitive prostate cancer.
Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment
By Hyunseok Kang, MD, MPH
Head and neck cancer treatment has historically advanced roughly once a decade, but two meaningful updates are arriving together this year
Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment
By Hyunseok Kang, MD, MPH
Head and neck cancer treatment has historically advanced roughly once a decade, but two meaningful updates are arriving together this year
Immunotherapy Is Moving Earlier Into Head and Neck Cancer Treatment
By Hyunseok Kang, MD, MPH
Head and neck cancer treatment has historically advanced roughly once a decade, but two meaningful updates are arriving together this year